Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism

Tsuyoshi Yoshida, Yasuo Kuwabara, Yuichi Ichiya, Masayuki Sasaki, Toshimitsu Fukumura, Atsushi Ichimiya, Masashi Takita, Koji Ogomori, Kouji Masuda

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We studied the cerebral muscarinic acetylcholinergic receptor (mACh-R) by means of 11C-N-methyl-4-piperidyl benzilate (11C-NMPB) and positron emission tomography (PET) in Alzheimer's disease (AD) cases, and the findings were compared with the cerebral blood flow (CBF) and the glucose metabolism (CMRGlc) to evaluate the relationship between the mACh-R and the CBF or the CMRGlc. The subjects consisted of 18 patients with AD and 18 age and sex matched normal volunteers. The patients were clinically diagnosed according to the criteria of the NINDS-ADRDA as having 'probable AD' and were thus classified into two groups (mild and moderate AD) according to the severity of dementia determined by DSM-III-R. The CBF was measured by (99m)TcHMPAO SPECT, and the CMRGlc was measured by 18FDG PET. The 11C-NMPB uptake was evaluated by the graphical method and the ratio method (ROIs/Cerebellum). A significant mAChR decrease and more severe CMRGlc decrease in the conical region was seen in mild and moderate AD. The decrease in the CBF was not as obvious as that in the mACh-R and the CMRGlc. Our study thus suggested that the mACh-R decreased in patients with AD, and that the 18FDG PET was the most sensitive method for detecting the degenerative regions in patients with AD.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalAnnals of Nuclear Medicine
Volume12
Issue number1
DOIs
Publication statusPublished - Feb 1998

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on <sup>11</sup>C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism'. Together they form a unique fingerprint.

  • Cite this